BridgeBio reported positive top‑line results from Propel 3: oral infigratinib achieved statistically significant gains in annualized height velocity in children with achondroplasia versus placebo. The trial met primary and key secondary endpoints, with treatment differences of roughly +1.74 to +2.10 cm/year reported in company disclosures and BioCentury coverage. BridgeBio said it will pursue regulatory submissions later this year and accelerate evaluation in related skeletal disorders. The oral mechanism — direct FGFR3 inhibition — offers a non‑injectable alternative to existing therapies such as BioMarin’s Voxzogo and a pending Ascendis contender, potentially intensifying competition in a narrow but high‑value rare‑disease market.